α-Synuclein-112 impairs synaptic vesicle recycling consistent with its enhanced membrane binding properties..
Cells and Development Biology; https://doi.org/10.3389/fcell.2020.00405.
Antioxidant Nanoparticles for Concerted Inhibition of α-Synuclein Fibrillization, and Attenuation of Microglial Intracellular Aggregation and Activation
Frontiers Bioengineering and Biotechnology; https://doi.org/10.3389/fbioe.2020.00112
RT-QuIC-based detection of alpha-synuclein seeding activity in brains of dementia with Lewy Body patients and of a transgenic mouse model of synucleinopathy.
Prion; doi: 10.1080/19336896.2020.1724608.
Hsc70 Ameliorates the Vesicle Recycling Defects Caused by Excess α-Synuclein at Synapses.
ENEURO; DOI: https://doi.org/10.1523/ENEURO.0448-19.2020.
Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson's disease.
Food & Function; DOI: 10.1039/c8fo00964c.
α-synuclein promotes progression of Parkinson's disease by upregulating autophagy signaling pathway to activate NLRP3 inflammasome.
Experimental and Therapeutic Medicine; https://doi.org/10.3892/etm.2019.8297.
Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model..
Alzheimers Dement.; doi: 10.1016/j.jalz.2019.02.002.
TREM2 deficiency aggravates α-synuclein–induced neurodegeneration and neuroinflammation in Parkinson’s disease models
FASEB J.; DOI: 10.1096/fj.201900992R.
Functionalization of the TMEM175 p.M393T Variant as a risk factor for Parkinson Disease
Hum Mol Genet.; DOI: 10.1093/hmg/ddz136.
Increased Immune Activation by Pathologic α‐Synuclein in Parkinson's Disease.
Annals of Neurology; https://doi.org/10.1002/ana.25557.